Aimmune Therapeutics (AIMT) Tops Q1 EPS by 3c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q1 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c